May 11, 2021 Share
A gene therapy that makes use of an unlikely helper, the AIDS virus, gave a working immune system to 48 babies and toddlers who were born without one, doctors reported Tuesday.
Results show that all but two of the 50 children who were given the experimental therapy in a study now have healthy germ-fighting abilities.
“We’re taking what otherwise would have been a fatal disease” and healing most of these children with a single treatment, said study leader Dr. Donald Kohn of UCLA Mattel Children’s Hospital.
“They’re basically ‘free range’ going to school, doing normal things,” without the worry that any infection could become life-threatening, he said.
Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results
Marker continues to advance Phase 2 AML trial, recently dosing first patient
Company closed financing extending cash runway into Q1 2023
Company to host conference call and webcast today at 5:00 p.m. ET
News provided by
Share this article
Share this article
HOUSTON, May 12, 2021 /PRNewswire/ Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the first quarter ended March 31, 2021. We had a productive first quarter supported by our recently completed financing, strengthening our overall cash position and enabling continued growth and expansion of our Multi-TAA pipeline, said Peter L. Hoang, President & CEO of Marker Therapeutics. In add
AIDS virus used in gene therapy to fix bubble baby disease
The one-time treatment involves using a disabled version of the AIDS virus to deliver a gene the kids lack to form an immune system. Author: MARILYNN MARCHIONE AP Chief Medical Writer Published: 6:20 AM EDT May 11, 2021 Updated: 6:20 AM EDT May 11, 2021
WASHINGTON A gene therapy that makes use of an unlikely helper, the AIDS virus, gave a working immune system to 48 babies and toddlers who were born without one, doctors reported Tuesday.
Results show that all but two of the 50 children who were given the experimental therapy in a study now have healthy germ-fighting abilities.
Search jobs 11-May-2021 M6P Therapeutics Presents M002 Gene Therapy Preclinical Proof-of-Concept Data for the Treatment of Mucolipidosis Type II at the ASGCT 24th Annual Meeting
- Preclinical data provide proof of concept for M002 to restore cellular uptake and lysosomal delivery and attenuate phenotype in mouse models of mucolipidosis type II -
- M002 leverages the Company’s proprietary S1S3 bicistronic platform technology in an AAV9 gene therapy to restore mannose 6-phosphate recognition marker on lysosomal enzymes -
ST. LOUIS, Mo. (BUSINESS WIRE) M6P Therapeutics (“the Company”), a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), today announced the presentation of preclinical proof-of-concept data for M002, its gene therapy candidate for mucolipidosis type II (MLII), at the American Society of Gene & Cell Therapy (ASGCT) 24
Gene therapy uses AIDS virus to help children born with bubble baby disease baltimoresun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from baltimoresun.com Daily Mail and Mail on Sunday newspapers.